ReviewNucleic acid therapeutics2012
RNA interference trigger variants: getting the most out of RNA for RNA interference-based therapeutics.
Review in Nucleic acid therapeutics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Gene therapy for pediatric genetic kidney diseases.Pediatric discovery · 2023Review
- Article
- Article
- RNA Interference Therapies for an HIV-1 Functional Cure.Viruses · 2017Review
- TLR9-Targeted SiRNA Delivery In Vivo.Methods in molecular biology (Clifton, N.J.) · 2016Article
- Technologies for controlled, local delivery of siRNA.Journal of controlled release : official journal of the Controlled Release Society · 2015Review
- Effective inhibition of HIV-1 production by short hairpin RNAs and small interfering RNAs targeting a highly conserved site in HIV-1 Gag RNA is optimized by evaluating alternative length formats.Antimicrobial agents and chemotherapy · 2015Article
- Lipid nanoparticle delivery systems for siRNA-based therapeutics.Drug delivery and translational research · 2014Article
- Molecular basis for improved gene silencing by Dicer substrate interfering RNA compared with other siRNA variants.Nucleic acids research · 2013Article
- Technologies for investigating the physiological barriers to efficient lipid nanoparticle-siRNA delivery.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2013Review
- Inhibition of Sox2 Expression in the Adult Neural Stem Cell Niche In Vivo by Monocationic-based siRNA Delivery.Molecular therapy. Nucleic acids · 2013Article
- Optimal choice of functional and off-target effect-reduced siRNAs for RNAi therapeutics.Frontiers in genetics · 2013Article
- Design of siRNA Therapeutics from the Molecular Scale.Pharmaceuticals (Basel, Switzerland) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The manifestation of RNA interference (RNAi)-based therapeutics lies in safe and successful delivery of small interfering RNAs (siRNAs), the molecular entity that triggers and guides sequence-specific degradation of target mRNAs. Optimizing the chemistry and structure of siRNAs to achieve maximum efficacy is an important parameter in the development of siRNA therapeutics. The RNAi protein machinery can tolerate a variety of non-canonical modifications made to siRNAs, each of which imparts advantageous properties. Here, we review these modifications to siRNAs in pre-clinical and clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.